Cargando…
DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
Baricitinib is a small molecule used to treat moderate to severe rheumatoid arthritis (RA) in adults. It is an inhibitor of Janus kinase 1 and 2 (JAK1 and JAK2). It has also been repurposed as a potential treatment for Covid 19. The current study has been carried out to understand the structural and...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395141/ https://www.ncbi.nlm.nih.gov/pubmed/36032699 http://dx.doi.org/10.1016/j.matpr.2022.04.868 |
_version_ | 1784771624475557888 |
---|---|
author | Sonia, Chiging Devi, Th.Gomti Karlo, T. |
author_facet | Sonia, Chiging Devi, Th.Gomti Karlo, T. |
author_sort | Sonia, Chiging |
collection | PubMed |
description | Baricitinib is a small molecule used to treat moderate to severe rheumatoid arthritis (RA) in adults. It is an inhibitor of Janus kinase 1 and 2 (JAK1 and JAK2). It has also been repurposed as a potential treatment for Covid 19. The current study has been carried out to understand the structural and chemical properties of this molecule. The molecule is optimized by using density functional theory (DFT) method. The DFT calculations are performed using Gaussian 09 W software package. The bond lengths and bond angles between atoms in the molecules are investigated. The intramolecular interaction within the molecule is identified using the natural bond orbital (NBO) study. The atom in molecule (AIM) study is performed using Multiwfn software. All the calculations are performed at B3LYP /6311G++ (d, p) level of theory. The molecular parameters, such as first-order hyperpolarizability, HOMO-LUMO energy gap, global electrophilicity index, dipole moment, chemical potential, hardness, ionization energy and electron affinity are determined from the calculation. The molecular docking analysis of Baricitinib is also carried out against different target proteins such as 6VSB, 6W9C and 6LU7. |
format | Online Article Text |
id | pubmed-9395141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93951412022-08-23 DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib Sonia, Chiging Devi, Th.Gomti Karlo, T. Mater Today Proc Article Baricitinib is a small molecule used to treat moderate to severe rheumatoid arthritis (RA) in adults. It is an inhibitor of Janus kinase 1 and 2 (JAK1 and JAK2). It has also been repurposed as a potential treatment for Covid 19. The current study has been carried out to understand the structural and chemical properties of this molecule. The molecule is optimized by using density functional theory (DFT) method. The DFT calculations are performed using Gaussian 09 W software package. The bond lengths and bond angles between atoms in the molecules are investigated. The intramolecular interaction within the molecule is identified using the natural bond orbital (NBO) study. The atom in molecule (AIM) study is performed using Multiwfn software. All the calculations are performed at B3LYP /6311G++ (d, p) level of theory. The molecular parameters, such as first-order hyperpolarizability, HOMO-LUMO energy gap, global electrophilicity index, dipole moment, chemical potential, hardness, ionization energy and electron affinity are determined from the calculation. The molecular docking analysis of Baricitinib is also carried out against different target proteins such as 6VSB, 6W9C and 6LU7. Elsevier Ltd. 2022 2022-05-11 /pmc/articles/PMC9395141/ /pubmed/36032699 http://dx.doi.org/10.1016/j.matpr.2022.04.868 Text en Copyright © 2022 Elsevier Ltd. All rights reserved. Selection and peer-review under responsibility of the scientific committee of the XII th Biennial National Conference of Physics Academy of North East (PANE 2021). Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Sonia, Chiging Devi, Th.Gomti Karlo, T. DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib |
title | DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib |
title_full | DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib |
title_fullStr | DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib |
title_full_unstemmed | DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib |
title_short | DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib |
title_sort | dft study on the structural and chemical properties of janus kinase inhibitor drug baricitinib |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395141/ https://www.ncbi.nlm.nih.gov/pubmed/36032699 http://dx.doi.org/10.1016/j.matpr.2022.04.868 |
work_keys_str_mv | AT soniachiging dftstudyonthestructuralandchemicalpropertiesofjanuskinaseinhibitordrugbaricitinib AT devithgomti dftstudyonthestructuralandchemicalpropertiesofjanuskinaseinhibitordrugbaricitinib AT karlot dftstudyonthestructuralandchemicalpropertiesofjanuskinaseinhibitordrugbaricitinib |